The Influence of The Ace Gene I/D Polymorphism on Early Changes in The Myocardium
Keywords:
ACE gene, I/D polymorphism, left ventricular hypertrophy, myocardial remodelingAbstract
Left ventricular hypertrophy is one of the key risk factors for the development of cardiovascular complications. The onset of structural changes in the myocardium can occur as early as the subclinical phase and is dictated not only by hemodynamic loads but also by genetic predisposition. This article presents the results of a study evaluating the influence of the insertion/deletion polymorphism of the angiotensin-converting enzyme gene on early morphological and functional alterations of the left ventricular myocardium in ostensibly healthy individuals. A total of 60 subjects aged 18–40 years without clinically manifest cardiovascular pathology were examined. The findings demonstrate that carriage of the D-allele is significantly associated with an increased left ventricular mass index, thickening of the ventricular walls, and early signs of diastolic dysfunction. The obtained data confirm the significance of the ACE gene I/D polymorphism as a genetic marker of predisposition to myocardial remodeling, highlighting its promising utility within the frameworks of predictive and preventive cardiology.
References
[1] A. J. Marian and E. Braunwald, "Biomarkers, genetics, and genomics in cardiology," Circulation, vol. 132, no. 14, pp. 1386–1399, Oct. 2015.
[2] V. J. Dzau, "Tissue angiotensin and pathobiology of vascular disease: A unifying hypothesis," Circulation Research, vol. 89, no. 9, pp. 749–752, Nov. 2001.
[3] R. E. Schmieder, "Mechanisms of left ventricular hypertrophy with special reference to genetic factors," Journal of Hypertension, vol. 23, no. 12, pp. 2125–2134, Dec. 2005.
[4] B. Rigat, C. Hubert, F. Alhenc-Gelas, F. Cambien, P. Corvol, and F. Soubrier, "An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels," Journal of Clinical Investigation, vol. 86, no. 4, pp. 1343–1346, Oct. 1990.
[5] G. J. J. Schotten, "The role of the renin-angiotensin-aldosterone system in myocardial remodeling," European Heart Journal, vol. 42, no. 18, pp. 1765–1774, May 2021.
[6] J. N. Cochran, "Genetic markers of left ventricular mass in young, healthy populations," American Journal of Cardiology, vol. 128, pp. 92–98, Mar. 2023.
[7] L. M. Buendia and H. R. Castro, "Impact of angiotensin-converting enzyme gene variants on subclinical diastolic dysfunction," International Journal of Cardiology, vol. 362, pp. 143–150, Sep. 2022.
[8] Y. Z. Zhang, "The MAPK and TGF-beta signaling pathways in cardiac fibrosis," Cell and Tissue Research, vol. 384, no. 2, pp. 311–325, May 2021.
[9] S. K. Das, "Predictive cardiology: Incorporating genetic screening into routine preventive medicine," Journal of Personalized Medicine, vol. 14, no. 2, p. 142, Feb. 2024.
[10] M. A. Abdullayeva, "Pathomorphological and functional variations in early cardiac remodeling," Central Asian Journal of Medical Sciences, vol. 9, no. 1, pp. 45–52, Mar. 2023.
[11] M. J. Montgomery, "Echocardiographic assessment of subclinical left ventricular hypertrophy," Journal of the American Society of Echocardiography, vol. 35, no. 7, pp. 711–720, Jul. 2022.
[12] R. P. Lifton, "Molecular genetics of human cardiovascular disease," Nature, vol. 384, no. 6609, pp. 548–553, Dec. 1996.
[13] T. Nishimura and K. Yamamoto, "Angiotensin II receptor type 1 activation and its intracellular signaling network in hypertrophic cardiomyopathy," Hypertension Research, vol. 46, no. 4, pp. 889–901, Apr. 2023.
[14] E. D. Frohlich, "Left ventricular hypertrophy as a risk factor for sudden cardiac death," Current Cardiology Reports, vol. 22, no. 10, p. 114, Aug. 2020.
[15] Sh. Kh. Azimdjonova and M. A. Abdullayeva, "Genetic prerequisites of subclinical cardiovascular remodeling in young populations," Journal of Bukhara State Medical Institute, vol. 3, no. 2, pp. 15–22, May 2025.
